Paper Details

  1. Home
  2. Paper Details

The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized study.

Author: HallakRon, NaftaliTimna, NivEva, VaismanNachum

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

IBS symptoms did not improve with probiotic treatment with L. reuteri.
Paper Details　
Original Abstract of the Article :
BACKGROUND: It was suggested that the intestinal microflora may play a role in the pathogenesis of irritable bowel syndrome (IBS). Probiotics may ease symptoms in IBS patients by changing gut microflora, reducing mucosal inflammation and exerting antibacterial effects. AIM: To assess the short- and...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.clnu.2005.06.001

データ提供：米国国立医学図書館（NLM）

Lactobacillus Reuteri for Irritable Bowel Syndrome

This double-blind, placebo-controlled, randomized study investigates the efficacy of Lactobacillus reuteri ATCC 55730, a probiotic strain, in treating patients with irritable bowel syndrome (IBS). The study explores the short- and long-term effects of L. reuteri on the severity of IBS symptoms.

L. Reuteri: Limited Evidence for IBS Treatment

Despite a potential role for the gut microbiome in IBS, this study found no significant improvement in IBS symptoms with L. reuteri treatment. Both the treatment and placebo groups showed improvement, suggesting a strong placebo effect. The study highlights the need for further research to clarify the potential of probiotics in treating IBS.

A Search for Relief in the Desert of Gut Health

Imagine IBS as a harsh desert environment, where the balance of the gut microbiome is disrupted, leading to uncomfortable symptoms. This study explores the potential of L. reuteri as a guide through this desert, seeking to restore balance and alleviate IBS symptoms. While the study did not find conclusive evidence for L. reuteri's effectiveness, it emphasizes the importance of exploring diverse approaches to managing IBS and the complexity of the gut microbiome's role in health and disease.

Dr. Camel's Conclusion

This study serves as a reminder that the desert of gut health is vast and complex, requiring a nuanced understanding of the microbiome and its interaction with IBS symptoms. While L. reuteri may not be the definitive solution, it highlights the ongoing search for effective probiotic therapies to improve gut health and alleviate the discomfort of IBS.
Date :
  1. Date Completed 2006-03-10
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

16051399

DOI: Digital Object Identifier

10.1016/j.clnu.2005.06.001

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.